EE04873B1 - Interferoon-beeta valku kodeerivat geeni sisaldava viirusvektori ja replikatsioonipuudega viirusvektori kasutamine - Google Patents

Interferoon-beeta valku kodeerivat geeni sisaldava viirusvektori ja replikatsioonipuudega viirusvektori kasutamine

Info

Publication number
EE04873B1
EE04873B1 EEP200000102A EEP200000102A EE04873B1 EE 04873 B1 EE04873 B1 EE 04873B1 EE P200000102 A EEP200000102 A EE P200000102A EE P200000102 A EEP200000102 A EE P200000102A EE 04873 B1 EE04873 B1 EE 04873B1
Authority
EE
Estonia
Prior art keywords
viral vector
interferon
gene encoding
beta protein
vector containing
Prior art date
Application number
EEP200000102A
Other languages
English (en)
Estonian (et)
Inventor
G. Barsoum James
Xiao Qin Albert
Original Assignee
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated
Publication of EE200000102A publication Critical patent/EE200000102A/xx
Publication of EE04873B1 publication Critical patent/EE04873B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200000102A 1997-08-29 1998-08-25 Interferoon-beeta valku kodeerivat geeni sisaldava viirusvektori ja replikatsioonipuudega viirusvektori kasutamine EE04873B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5725497P 1997-08-29 1997-08-29
PCT/US1998/017606 WO1999010516A2 (en) 1997-08-29 1998-08-25 Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta

Publications (2)

Publication Number Publication Date
EE200000102A EE200000102A (et) 2000-12-15
EE04873B1 true EE04873B1 (et) 2007-08-15

Family

ID=22009467

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000102A EE04873B1 (et) 1997-08-29 1998-08-25 Interferoon-beeta valku kodeerivat geeni sisaldava viirusvektori ja replikatsioonipuudega viirusvektori kasutamine

Country Status (25)

Country Link
EP (1) EP1007717B8 (xx)
JP (3) JP4124565B2 (xx)
KR (1) KR100699285B1 (xx)
CN (1) CN100342019C (xx)
AT (1) ATE316145T1 (xx)
AU (1) AU740428B2 (xx)
BR (1) BR9812138A (xx)
CA (1) CA2300480C (xx)
CY (1) CY1105029T1 (xx)
CZ (2) CZ299095B6 (xx)
DE (1) DE69833264T2 (xx)
DK (1) DK1007717T3 (xx)
EA (1) EA003256B1 (xx)
EE (1) EE04873B1 (xx)
ES (1) ES2257817T3 (xx)
HK (1) HK1029599A1 (xx)
HU (1) HU224422B1 (xx)
IL (2) IL134593A0 (xx)
IS (1) IS2318B (xx)
NO (1) NO20000990L (xx)
NZ (1) NZ503401A (xx)
PT (1) PT1007717E (xx)
SK (1) SK286821B6 (xx)
TR (1) TR200000532T2 (xx)
WO (1) WO1999010516A2 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2283524T3 (es) * 2001-01-22 2007-11-01 Biogen Idec Ma Inc. Metodo para mejorar el suministro de un acido nucleico terapeutico.
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
EP1835032A1 (en) * 2006-03-14 2007-09-19 Université de Liège A self-inactivating recombinant lentiviral vector for the inhibition of HIV replication
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
CN103505722B (zh) * 2012-06-19 2016-04-13 苏州丁孚靶点生物技术有限公司 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法
WO2017214706A1 (en) * 2016-06-15 2017-12-21 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
WO2020247321A1 (en) * 2019-06-01 2020-12-10 Sivec Biotechnologies, Llc A bacterial platform for delivery of gene-editing systems to eukaryotic cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
DE69531387T2 (de) * 1994-08-16 2004-04-22 Crucell Holland B.V. Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence

Also Published As

Publication number Publication date
JP2005225888A (ja) 2005-08-25
AU740428B2 (en) 2001-11-01
CA2300480C (en) 2010-01-05
JP3953458B2 (ja) 2007-08-08
CN100342019C (zh) 2007-10-10
ES2257817T3 (es) 2006-08-01
EP1007717A2 (en) 2000-06-14
SK286821B6 (sk) 2009-06-05
PT1007717E (pt) 2006-06-30
IL134593A0 (en) 2001-04-30
SK2482000A3 (en) 2000-08-14
DE69833264T2 (de) 2006-09-28
HU224422B1 (hu) 2005-08-29
WO1999010516A2 (en) 1999-03-04
NZ503401A (en) 2003-01-31
EA003256B1 (ru) 2003-02-27
EP1007717B1 (en) 2006-01-18
JP2001514010A (ja) 2001-09-11
KR20010023511A (ko) 2001-03-26
CN1271391A (zh) 2000-10-25
DK1007717T3 (da) 2006-05-29
JP4219335B2 (ja) 2009-02-04
HUP0002913A2 (hu) 2000-12-28
AU9205198A (en) 1999-03-16
CY1105029T1 (el) 2010-03-03
IS5374A (is) 2000-02-11
ATE316145T1 (de) 2006-02-15
BR9812138A (pt) 2000-07-18
NO20000990D0 (no) 2000-02-28
HUP0002913A3 (en) 2003-08-28
NO20000990L (no) 2000-05-02
EA200000270A1 (ru) 2000-10-30
HK1029599A1 (en) 2001-04-06
DE69833264D1 (de) 2006-04-06
EE200000102A (et) 2000-12-15
CA2300480A1 (en) 1999-03-04
TR200000532T2 (tr) 2000-11-21
EP1007717B8 (en) 2006-05-03
JP2004155786A (ja) 2004-06-03
KR100699285B1 (ko) 2007-03-26
CZ299095B6 (cs) 2008-04-23
IS2318B (is) 2007-11-15
CZ2000733A3 (cs) 2000-06-14
IL134593A (en) 2007-06-17
CZ297314B6 (cs) 2006-11-15
JP4124565B2 (ja) 2008-07-23
WO1999010516A3 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
CY1105029T1 (el) Μεθοδοι και συνθεσεις για θεραπειες καρκινου χρησιμοποιωντας γονιδια που κωδικοποιουν εκκρινομενες πρωτεϊνες οπως ιντερφερονη-βητα
DE69426328T2 (de) Verwendung von mesothelialen zellen in der gentherapie
DE69230993T2 (de) Rekombinante viren vektoren zur expression in muskelzellen
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
FI932678A (fi) Pao alfavirus baserande dna expressionssystem
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
CY1108459T1 (el) Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων
DE69830251D1 (de) Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen
NO991839L (no) FremgangsmÕter og preparater for utlevering og ekspresjon av interferon-<alfa>-nukleinsyrer
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use
DE69910809D1 (de) Verwendung von OmpA Enterobakterproteinen um zielgerichtet Antigen-Präsentierende Zellen anzusteuern
FI950516A (fi) Interferoni-alfa/beta-sitojaproteiini, sen valmistus ja käyttö

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20090825